Amgen’s ITC Complaint Against Roche’s Peg-EPO Dismissed
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. International Trade Commission ruling finds that Roche’s CERA is subject to a clinical trial exemption from patent infringement.
You may also be interested in...
Aranesp Sales Down As Physicians Adopt Wait-And-See Posture – Amgen
Nineteen percent decline in U.S. sales of the erythropoiesis-stimulating agent versus Q2 2006 is a response to labeling change, regulatory climate, Amgen exec says.
Aranesp Sales Down As Physicians Adopt Wait-And-See Posture – Amgen
Nineteen percent decline in U.S. sales of the erythropoiesis-stimulating agent versus Q2 2006 is a response to labeling change, regulatory climate, Amgen exec says.
Roche’s Renal Anemia Studies Show Benefits Of CERA Once-Monthly Dosing
The continuous erythropoietin receptor activator is to be marketed under the trade name Mircera.